NORSPAN Transdermal Patches Phase III Study In Non-Cancer Pain

Inclusion Criteria: * Males or females age are ≥20 ,≤80 years. * Clinical diagnosis of musculoskeletal pain for 4 weeks or longer with non-malignant pain etiology at Visit 1. * Subject is a current user of NSAIDS or paracetamol and reports a history of insufficient therapeutic benefit in musculoskeletal pain. * Subjects must record an 'average pain over the last week at study institution' score at primary pain site of ≥ 4 on an 11-point numerical pain rating scale. * Subjects must be able to understands the study procedures and assessment, and agree to participate in the study by giving written informed consent. Exclusion Criteria: * Subjects who have been taking long-acting or short-acting opioid analgesic formulations within the last 4 weeks. * Subjects who have a current chronic disease(s) or who have a past history and high possibilities to relapse, in addition to their musculoskeletal pain, requiring frequent analgesic therapy. * Subjects with clinically unstable respiratory disease, dysfunction of the biliary tract, thyroid disease, adrenal cortical insufficiency, prostatic hypertrophy requiring intervention or renal artery stenosis. * Subject who have a past history of malignant neoplasm including leukemia and lymphoma. * Subjects with clinically unstable, active or symptomatic heart disease. * Subjects who have psychiatric disorder, uncontrolled seizures or convulsive disorder and so on. * Subjects who have a current or past (within 5 years) history of substance or alcohol abuse, or subjects who give a positive result in drug abuse test during the Screening Period. * Subjects scheduled for therapies within the study period which might effect study assessment. * Females who are pregnant, lactating or have a possibility of being pregnant. * Subjects with values \> 2 times the upper limit of normal for AST or ALT or total bilirubin at visit 1 or who have severe impaired liver function. * Subjects with serum creatinine \> 2 mg/dL at Visit 1 or who have severe impaired renal function. * Subjects with serum potassium \< 3.5 mEq/L at Visit 1. * Subjects receiving hypnotics or other central nervous system (CNS) depressants. * Subjects receiving monoamine oxidase inhibitor (MAOI) within 2 weeks before screening. * Subjects who have a history of supersensitivity to study drug. * Known intolerance to and/or lack of effect of tramadol. * Subjects who participated in a clinical research study within 1 month of study entry. * Subjects who participated previously in a BTDS study.